Compare iShares International Treasury Bond ETF (IGOV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs ResMed Inc. — how do they compare? iShares International Treasury Bond ETF trades at $39.71 (market cap $1.30B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 24.5× iShares International Treasury Bond ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and ResMed Inc. for 51 Days on average.
| IGOV | RMD | |
|---|---|---|
Market Cap | $1.30B | $31.89B |
Volume | 693,740 | 618,314 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $277.88 |
52-Week Low | $39.65 | $182.82 |
Typical Hold Time | 92 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.67, down 0.08% with a bearish technical signal from moving averages, while oscillators are neutral. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights rising global bond yields, which may impact interest rate-sensitive stocks.
The outlook is cautious due to missing financial data and bearish technicals. Risks include macroeconomic pressure from higher yields, while opportunities depend on future earnings visibility. Investors need updated financials to assess valuation and growth prospects accurately.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
